Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...

Women with breast cancer and 1-2 sentinel lymph node macrometastases can safely skip completion axillary lymph node dissection (ALND) without compromising overall survival or arm function, according ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Despite advances in the treatment of breast cancer, there is little research examining the prevention of lymphedema after breast and/or axillary surgery. Currently, there are no national guidelines ...

Please provide your email address to receive an email when new articles are posted on . Patients with breast cancer had similar survival whether they underwent completion axillary lymph node ...

Researchers from Heidelberg University Hospital and the University of Lucerne as well as international scientists, patient representatives and European cancer societies have pooled scientific data and ...